Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Avacta Group plc ( (GB:AVCT) ) has shared an announcement.
Avacta Group plc has announced that it will release its unaudited interim results for the first half of 2025 on September 30, with a live presentation by its CEO and CFO accessible to shareholders and potential investors. Additionally, the company has updated the schedule for its presentation at the European Society for Medical Oncology Congress, where it will discuss its Phase I trial of FAP-Dox (AVA6000) in patients with FAP-positive solid tumors. These announcements highlight Avacta’s ongoing efforts to engage with stakeholders and advance its position in the oncology drug development sector.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £47.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Spark’s Take on GB:AVCT Stock
According to Spark, TipRanks’ AI Analyst, GB:AVCT is a Neutral.
Avacta Group plc’s overall stock score is influenced primarily by its financial challenges, which weigh heavily despite some positive technical indicators and strategic progress in its oncology focus. The need for additional funding and financial losses are significant concerns, while technical trends provide some short-term optimism.
To see Spark’s full report on GB:AVCT stock, click here.
More about Avacta Group plc
Avacta Group plc is a clinical-stage life sciences company focused on developing innovative oncology drugs. The company leverages its proprietary pre|CISION® platform, which utilizes a tumor-specific protease, fibroblast activation protein (FAP), to deliver highly potent cancer therapies directly to the tumor microenvironment, minimizing damage to healthy tissues. Avacta’s pipeline includes peptide drug conjugates (PDC) and Affimer® drug conjugates (AffDC) that offer advantages over traditional antibody drug conjugates.
Average Trading Volume: 2,682,981
Technical Sentiment Signal: Hold
Current Market Cap: £224.4M
Find detailed analytics on AVCT stock on TipRanks’ Stock Analysis page.